Skip to main content

Market Overview

FDA Ok's Roche's Companion Diagnostic For Pfizer's Lorbrena In Lung Cancer

  • The FDA has approved Roche Holdings AG's (OTCMKT: RHHBY) Ventana ALK (D5F3) CDx Assay as a companion diagnostic to identify ALK-positive non-small cell lung cancer patients eligible for treatment with Pfizer Inc's (NYSE: PFE) Lorbrena (lorlatinib).
  • The assay is intended for the qualitative detection of the anaplastic lymphoma kinase (ALK) protein in formalin-fixed, paraffin-embedded non-small cell lung cancer tissue.
  • It is indicated as an aid in identifying patients eligible for treatment with PFE's Xalkori (crizotinib), Novartis AG's (NYSE: NVS) Zykadia (ceritinib), Roche's Alecensa (alectinib), or Lorbrena in the U.S.
  • Price Action: RHHBY shares closed 1.2% lower at $40.12 on Monday.

Related Articles (RHHBY + RHHBF)

View Comments and Join the Discussion!

Posted-In: lung cancerBiotech News Health Care FDA General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at